Aptose Biosciences Doses First Patient in Re-Initiation of Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies Nov 26, 2018 7:05am EST
Aptose to Participate in Upcoming Investor Conferences, Host Key Opinion Leader Event, and Present Data at the Upcoming ASH Meeting Nov 20, 2018 7:05am EST
Aptose to Release Third Quarter Ended September 30, 2018 Financial Results on November 6, 2018 Oct 23, 2018 7:05am EDT
Aptose Biosciences and CrystalGenomics Announce Issuance of European Patent for CG-806 Sep 27, 2018 7:05am EDT
